Iovance Biotherapeutics, Inc.
NASDAQ:IOVABiotechnology
-$0.04 today
- Market cap
- $3.46B
- Beta
- 0.70
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.85
Volume 6.99M
Average 14.09M
IOVA Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Iovance Biotherapeutics, Inc.NASDAQ: IOVA
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income declines year over year
Q3 FY2026 net income of $22.27M (cash outflow) fell 75.6% year over year, behind the -44.5% change in trailing-twelve-month net income. Sequentially, it fell 52.9% from the prior quarter. Over 3 fiscal years it compounded at -0.4% a year.
Context
- Net income amounted to 148.4% of revenue in FY2025, down 78.5 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of -$169.06M (-56.8%) for the fiscal year ending Dec 2026, a slowdown from the +5.1% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$22.27M-52.9% QoQ
- Last fiscal yearDec 2025
- -$390.98M+5.1% YoY
- LTMSep 2026
- -$220.54M-44.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -75.6% | -72.1% | +3.5 pp |
| 1 year | +5.1% | -56.8% | -61.8 pp |
| 3-year CAGR | -0.4% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (390.98M) USD
- Year-over-year change
- -5.1%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (390.98M) | -5.1% |
| FY2024 | 2024-12-31 | (372.18M) | +16.2% |
| FY2023 | 2023-12-31 | (444.04M) | -12.2% |
| FY2022 | 2022-12-31 | (395.89M) | -15.7% |
| FY2021 | 2021-12-31 | (342.25M) | — |
Net Income vs competitors
How IOVA compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -44.5% is the 9th highest of 10, against a peer median of +26.9%.
- Net income amounts to 58.2% of revenue for IOVA, versus a peer median of 64.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €1.71B EUR | +348.2% | — | 64.7% | |
| LTM Sep 2026 | $1.11B USD | +218.3% | -5.5% | 607.8% | |
| LTM Jun 2026 | $861.1M USD | — | -48.4% | 20.8% | |
| LTM Dec 2025 | $314.85M USD | +37.9% | +28.0% | — | |
| LTM Sep 2026 | $282.65M USD | +26.9% | +79.2% | — | |
| LTM Sep 2026 | $220.54M USD | -44.5% | -0.4% | 58.2% | |
| LTM Mar 2026 | $129.91M USD | -26.1% | -21.5% | 2056.8% | |
| LTM Mar 2026 | $88.87M USD | -31.7% | -6.3% | — | |
| LTM Mar 2026 | $49.87M USD | -29.4% | -21.8% | 4987.4% | |
| LTM Mar 2026 | $27.59M USD | +28.8% | -20.5% | 7.2% | |
| LTM Sep 2026 | $2.81M USD | -98.7% | -12.6% | 0.2% | |
| Peer median (excluding IOVA) | — | +26.9% | -12.6% | 64.7% | |
Competitors are the stored peer set for IOVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (342.25M) | (395.89M) | (444.04M) | (372.18M) | (390.98M) |
| Depreciation & Amortization | 13.98M | 21.14M | 33.13M | 43.61M | 47.32M |
| Deferred Income Tax | 0 | 0 | (3.48M) | (2.83M) | (2.07M) |
| Stock-Based Compensation | 69.77M | 84.02M | 62.63M | 109.63M | 61.58M |
| Change in Working Capital | 24.55M | (2.89M) | (6.52M) | (122.56M) | (24.27M) |
| Accounts Receivables | 0 | 0 | (149K) | (69.19M) | (13.11M) |
| Inventory | 0 | 0 | (10.12M) | (39.92M) | (14.21M) |
| Accounts Payables | 6.98M | 5.88M | 4.83M | (7.84M) | (6.66M) |
| Other Working Capital | 17.58M | (8.78M) | (1.08M) | (5.61M) | 9.71M |
| Other Non-Cash Items | 6.01M | 871K | (3.54M) | (8.65M) | 6.01M |
| Operating Cash Flow | (227.94M) | (292.76M) | (361.82M) | (352.98M) | (302.41M) |
| Capital Expenditures | (37.57M) | (20.43M) | (22.29M) | (11.07M) | (33.84M) |
| Acquisitions (Net) | (37.71M) | (276.88M) | (212.63M) | (52.57M) | 0 |
| Purchases of Investments | (725.21M) | (245.82M) | (205.9M) | (460.77M) | (318.67M) |
| Sales of Investments | 762.91M | 522.7M | 285.58M | 428M | 400M |
| Other Investing Activities | 37.71M | 276.88M | 0 | 0 | 0 |
| Investing Cash Flow | 132K | 256.46M | (155.24M) | (96.41M) | 47.5M |
| Debt Repayment | 1M | 0 | 0 | 0 | 0 |
| Common Stock Issued | 203.16M | 189.5M | 463.28M | 397.3M | 306.31M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 35.11M | 648K | (322K) | (6.64M) | (7.06M) |
| Financing Cash Flow | 239.27M | 190.15M | 462.96M | 390.66M | 300.77M |
| Effect of Forex Changes | 0 | 0 | (2.74M) | (541K) | 1.52M |
| Net Change in Cash | 11.46M | 153.85M | (56.84M) | (59.27M) | 47.38M |
| Free Cash Flow | (265.52M) | (313.18M) | (384.11M) | (364.05M) | (336.24M) |
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
Intrinsic Alpha fair value
Locked
Current Price
$7.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.